Biognosys and Alamar Biosciences Forge Strategic Partnership in Proteomics to Advance Biopharma and Precision Medicine Research
- None.
- None.
The strategic partnership between Biognosys and Alamar Biosciences signifies a notable advancement in the field of biofluid proteomics. The integration of Biognosys' DIA-MS platform with Alamar's NULISA assays could lead to significant improvements in the detection and quantification of low-abundance proteins, such as cytokines and chemokines, which are critical in understanding disease mechanisms and developing targeted therapies.
From an industry perspective, this collaboration is poised to enhance the capabilities of proteomics in clinical research. The potential to identify new biomarkers for diseases like Non-Small Cell Lung Cancer (NSCLC) could translate into better diagnostic tools and more personalized treatment options, which in turn may drive growth for both companies in the precision medicine market. The success of the proof-of-concept study in integrating data from both platforms suggests that this partnership could lead to commercially viable products and services, which would be of interest to investors monitoring the biotechnology sector.
The use of Biognosys' DIA-MS and Alamar's NULISA assays represents a dual approach to unraveling the complexities of the plasma proteome. The ability to cover the full dynamic range of protein abundance in plasma is a significant step forward in biomarker discovery and disease research. This could facilitate a deeper understanding of the pathophysiology of various conditions, potentially leading to breakthroughs in early disease detection and treatment.
For stakeholders, the implications of this partnership extend beyond the immediate commercial and scientific collaboration. The long-term benefits could include the acceleration of therapeutic development and a shift towards more predictive and preventative healthcare models. However, the scalability and cost-effectiveness of these technologies in clinical settings will be critical factors determining their adoption and impact on the market.
The announcement of the partnership between Biognosys and Alamar Biosciences may have a positive impact on investor sentiment, particularly as it highlights a successful proof-of-concept study and plans for further commercial and scientific collaboration. The focus on NSCLC, a disease with significant unmet medical needs, could position the companies favorably in a high-value segment of the healthcare market.
Investors should monitor the progression of this partnership closely, as the integration of these technologies into marketable products and services has the potential to capture a sizable share of the proteomics market. It is also worth noting that collaborations like this can often lead to increased interest from larger pharmaceutical companies, possibly resulting in acquisition opportunities or additional partnerships that can further enhance shareholder value.
- Strategic partnership expands Biognosys' services to include Alamar's NULISA assays as well as joint scientific research in biofluid-based proteomics
- Complementary value of Biognosys' DIA-MS unbiased proteomics platform and Alamar's game-changing immunoassay platforms to be presented at the AACR 2024 Annual Meeting
In the Industry Spotlight Theater session hosted by Alamar at the American Society for Cancer Research (AACR) 2024 Annual Meeting in
Building upon this successful proof-of-concept study, Biognosys and Alamar are planning to further collaborate both commercially and scientifically as part of their strategic partnership.
- NULISA Assay Services: Biognosys will offer NULISA assays from its state-of-the-art facility in
Switzerland for previously hard to measure cytokines, chemokines, as well as other important disease specific markers from plasma and biofluids. These ultra-high sensitivity assays enable precise quantification of low abundance proteins, providing researchers with valuable insights into complex biological processes. They complement unbiased DIA-MS analysis of thousands of plasma proteins to elucidate systemic host response, and other inflammation or disease-related protein-fold changes. - Research Collaboration: Biognosys and Alamar will embark on a joint research initiative to explore plasma biology. By leveraging Biognosys' unbiased discovery methods alongside Alamar's ultra-high sensitivity assays, the teams seek to unravel biological disease mechanisms by providing a more complete picture of the plasma proteome, enabling for the first time the coverage of essentially the complete dynamic range of protein abundance in plasma.
Oliver Rinner, Ph.D., Founder and CEO of Biognosys, expressed enthusiasm about the collaboration: "We are excited to join forces with Alamar to advance proteomics research. Our combined efforts will pave the way for breakthroughs in plasma biology by analyzing in an unbiased way more than 5,000 proteins together with panels of hundreds of well characterized cytokines and other high value low abundance proteins using highly specific NULISA assays. With this approach we are aiming to cover the whole dynamic range of plasma proteins."
"We are thrilled to partner with Biognosys to provide the research community with expanded access to proteomic insights from discovery through to clinical research," said Yuling Luo, Ph.D., Chairman, Founder and CEO of Alamar. "Biognosys is a leading provider of advanced mass spec proteomics services to researchers around the world, and we look forward to adding the highest sensitivity high-multiplex immunoassays to their plasma proteomics offering."
This partnership underscores the commitment of both companies to scientific excellence and their shared vision of advancing precision medicine through innovative technologies.
About Biognosys
At Biognosys, we believe that deep proteome insights hold the key to breakthrough discoveries that transform science for better lives. With our versatile portfolio of next-generation proteomics solutions, including the TrueDiscovery®, TrueTarget®, and TrueSignature® research service platforms, our flagship software Spectronaut®, and the PQ500™ kit, we make the proteome actionable to empower research, drug development, and clinical decision-making. Our solutions provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Our unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins with industry-leading precision, depth, and throughput. Through our strategic partnership with Bruker (Nasdaq: BRKR), we make proteomics globally accessible. For more information, visit biognosys.com.
About Alamar
Alamar Biosciences is a privately held life sciences company with a mission to power precision proteomics to enable the earliest detection of disease. The company's proprietary NULISA Platform along with the ARGO™ HT System work seamlessly with the latest advances in genomics to achieve single digit attomolar detection sensitivity, greatly surpassing the most sensitive protein detection technology on the market today. For more information, please visit alamarbio.com.
Investor contact:
investors@alamarbio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/biognosys-and-alamar-biosciences-forge-strategic-partnership-in-proteomics-to-advance-biopharma-and-precision-medicine-research-302107939.html
SOURCE Alamar Biosciences, Inc.
FAQ
What is the strategic partnership announced between Biognosys and Alamar Biosciences?
Where will the joint scientific research be presented?
What is the focus of the collaborative study presented at the AACR 2024 Annual Meeting?
What services will Biognosys offer as part of the partnership?
What is the goal of the joint research initiative between Biognosys and Alamar?
